Clinical Trial

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Name: Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program — clinical trial record (NCT05040373)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Protocol Amendment History 52 amendments

This ClinicalTrials.gov record has been amended 52 times since 2021-09-07; most recent amendment 2026-05-28.

Trial Details

NCT Number	NCT05040373
Lead Sponsor	Alnylam Pharmaceuticals
Conditions	Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy
Enrollment	10 participants
Start Date	2020-08-01
Primary Completion	2030-10-12 (estimated)
Study Completion	2030-10-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-01